The Types segment classifies treatments into antibiotic ear drops, steroid ear drops, combination antibiotic‑steroid formulations, oral systemic agents, and surgical interventions. Antibiotic drops, such as ciprofloxacin or ofloxacin, dominate the market due to their targeted antimicrobial action, capturing the largest share within the segment. Steroid drops, primarily used to reduce inflammation, represent a secondary but essential niche, especially in chronic cases. Combination products merge these mechanisms, offering a differentiated value proposition that appeals to clinicians seeking simplified regimens. Oral systemic agents are limited to severe or resistant infections, contributing a modest portion of sales. Surgical interventions, including canal debridement, occupy a small yet critical slice for refractory cases. Collectively, these product types define the market taxonomy of Outer Ear Infection Treatment, illustrating how each subtype supports distinct clinical pathways and collectively sustains the market’s overall economic footprint.